Figure 2.

SLC7A11-AS1 Scavenges ROS to Promote Cancer Stemness

(A–C) Effects of SLC7A11-AS1 knockdown on expressions of Oct4 and Nanog were determined by qRT-PCR (A and B) and western blot (C) in gemcitabine-resistant PDAC cells (n = 3). (D) Expressions of Oct4 and Nanog in tumor tissues (as described in Figure 1G) were determined by western blot (D). (E) Oncosphere-formation assay in SLC7A11-AS1-knockdown and control gemcitabine-resistant PDAC cells. Original magnification ×10. (F) qRT-PCR analysis of SLC7A11-AS1 expression in spheroids and paired attached PDAC cells (n = 3). (G) Flow cytometry analysis of ROS using probe DCFH-DA (upper) and western blot analysis of Oct4 and Nanog (bottom) in SLC7A11-AS1-knockdown and control PANC-1 cells treated with or without NAC (10 mM) for 48 h (n = 3). *p < 0.05, **p < 0.01, ***p < 0.001.